BiotechTube

IMGN632

Phase 1/2Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Blastic Plasmacytoid Dendritic Cell Neoplasm

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm

Trial Timeline

Jan 2, 2018 → Dec 30, 2026

NCT ID
NCT03386513

About IMGN632

IMGN632 is a phase 1/2 stage product being developed by AbbVie for Blastic Plasmacytoid Dendritic Cell Neoplasm. The current trial status is active. This product is registered under clinical trial identifier NCT03386513. Target conditions include Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm.

What happened to similar drugs?

2 of 13 similar drugs in Blastic Plasmacytoid Dendritic Cell Neoplasm were approved

Approved (2) Terminated (3) Active (9)
🔄CTL019NovartisPhase 3
❌Tisagenlecleucel + Blinatumomab + InotuzumabNovartisPhase 3
🔄CTL019NovartisPhase 3
🔄Blinatumomab + DexamthasoneAmgenPhase 3
🔄Blinatumomab + Blinatumomab + HyperCVADAmgenPhase 3
🔄Blinatumomab + Dexamethasone + Vincrisitne + Daunorubicin + Methotrexate + Ifosfamide + PEG-asparaginase + Erwinia-asparaginaseAmgenPhase 3
🔄Omitted Doxorubicin + Omitted Vincristine+Dexamethasone pulses + Inotuzumab Ozogamicin+Standard Maintenance Therapy + Imatinib + 6-tioguanine+Standard Maintenance Therapy + BlinatumomabAmgenPhase 3

Hype Score Breakdown

Clinical
9
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03386513Phase 1/2Active

Competing Products

20 competing products in Blastic Plasmacytoid Dendritic Cell Neoplasm

See all competitors
ProductCompanyStageHype Score
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
39
PemetrexedEli LillyPhase 2
35
VCL-CB01Astellas PharmaPhase 2
35
SHP674Kyowa KirinPhase 2
35
LY3039478 + Dexamethasone + PlaceboEli LillyPhase 1/2
32
Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort BJiangsu Hengrui MedicinePhase 2
42
Venetoclax + Navitoclax + Dexamethasone + Vincristine + Calaspargase Pegol + Dasatinib + Cytarabine + Blinatumomab + Methotrexate + Mercaptopurine + Cyclophosphamide + Etoposide + Leucovorin + Intrathecal Triples + Pegaspargase + Erwinia asparaginaseAbbViePhase 1/2
36
ABT-348 + ABT-348 + ABT-348 and azacitidine + ABT-348AbbViePhase 1
29
VenetoclaxAbbViePhase 1
29
Dexamethasone + Vincristine + Daunorubicin + Calaspargase pegol + Dasatinib + Venetoclax + Bortezomib + Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) + Cyclophosphamide + Cytarabine + Mercaptopurine + Nelarabine + Methotrexate + ThioguanineAbbViePhase 2
42
Venetoclax + TagraxofuspAbbViePhase 2
42
Navitoclax + Chemotherapy + VenetoclaxAbbViePhase 1
29
Venetoclax + Dexamethasone + Inotuzumab OzogamicinAbbViePhase 1
33
Dasatinib + Methotrexate + Prednisone + Rituximab + Venetoclax + BlinatumomabAbbViePhase 1
36
Capivasertib + Venetoclax + Intrathecal chemotherapyAbbViePhase 1/2
39
Selumetinib + DexamethasoneAstraZenecaPhase 1/2
24
AZD3632 + PosaconazoleAstraZenecaPhase 1/2
39
AZD0486AstraZenecaPhase 1/2
39
blinatumomab + pembrolizumabMerckPhase 1/2
32
Brentuximab Vedotin + PembrolizumabMerckPhase 2
27